PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today ...
InfoQ中国 on MSN
Rust 再下一城：Astro 7 重写编译器与 Markdown 流水线
面向内容的 Web 框架 Astro 发布了 Astro 7。该版本几乎完全聚焦于构建性能，随后发布的两个次要版本又对其进行了扩展。 此次更新的核心是转向原生工具链。.astro 编译器已使用 Rust 重写，Markdown 和 MDX ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
Royalty Pharma has secured a stake in another transthyretin-mediated (ATTR) amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered ...
Ionis and AstraZeneca’s phase 3 study of Wainua (eplontersen) in ATTR-CM missed its primary endpoint, showing no statistically significant benefit when added to standard of care. This drove ...
No treatment effect was observed in patients on baseline TTR stabilizer therapy; however, a nominally significant benefit was seen with eplontersen monotherapy vs placebo. Topline results were ...
AstraZeneca and Ionis Pharmaceuticals disclosed Thursday morning that their gene-silencing drug Wainua (eplontersen) failed the largest clinical trial ever conducted in transthyretin-mediated amyloid ...
BridgeBio Pharma is teaming up with BlackDoctor and HealthyWomen to highlight how the heart condition ATTR-cardiac amyloidosis (ATTR-CM) is being “systematically missed in women.” The condition is a ...
Claims-based analysis showed 64% of patients received ATTR-CM diagnosis ≥6 months after incident HF, with median delays approaching 1.4 years and longer using diuretic proxy. Diagnostic timeliness ...
Kevin M. Alexander, MD, reflects on ACC data for ATTR-CM and its implications for patient care, stressing that clinical trials and extension analyses show ATTR therapies extend survival, improve ...
In ATTR amyloidosis, a buildup of harmful proteins causes damage to tissues and organs throughout the body, including the heart. Over time, the condition can progress from stage 1, which may cause ...
Genetic testing is an important part of the diagnosis process for transthyretin cardiac amyloidosis (ATTR-CM). It’s not only key to managing your care but also helps you determine whether others in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results